New options in the treatment of respiratory syncytial virus disease

Journal of Infection

Volumn 71, Issue S1, 2015, Pages S80-S87

  Mejias, Asuncion ^a   Ramilo, Octavio ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Antivirals; Children; Immune response; Monoclonal antibodies; RSV

Indexed keywords

1 (2,3 DIHYDRO 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (2 FLUOROPHENYL)UREA; ADRENALIN; ALS 008176; ALX 0171; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; ASVASIRAN; BRONCHODILATING AGENT; BTA 9881; CYTOKINE; GS 5806; HELIOX; MDT 637; MEDI 557; MEDI 8897; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 131 2G; MOTAVIZUMAB; PALIVIZUMAB; RI 001; RIBAVIRIN; SALBUTAMOL; STEROID; TMC 353121; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; ASTHMA; BRONCHIOLITIS; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOGENESIS; INFECTION CONTROL; LICENSING; LUNG FUNCTION; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROPHYLAXIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SOCIAL SUPPORT; TREATMENT INDICATION; VIRUS LOAD; WHEEZING; CHILD; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD; HUMANS; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84930474353     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.04.025     Document Type: Article

References (75)

1. Heidema J., de Bree G.J., De Graaff P.M., van Maren W.W., Hoogerhout P., Out T.A., et al. Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol 2004, 85(Pt 8):2365-2374.
2. Rutigliano J.A., Rock M.T., Johnson A.K., Crowe J.E., Graham B.S. Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 2005, 337(2):335-343.
3. Magro M., Mas V., Chappell K., Vazquez M., Cano O., Luque D., et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci USA 2012, 109(8):3089-3094.
4. McLellan J.S., Chen M., Leung S., Graepel K.W., Du X., Yang Y., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013, 340(6136):1113-1117.
5. Corti D., Bianchi S., Vanzetta F., Minola A., Perez L., Agatic G., et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 2013 Sep 19, 501(7467):439-443.
6. Garcia C.G., Bhore R., Soriano-Fallas A., Trost M., Chason R., Ramilo O., et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010, 126(6):e1453-e1460.
7. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360(6):588-598.
8. Stein R.T., Sherrill D., Morgan W.J., Holberg C.J., Halonen M., Taussig L.M., et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999, 354(9178):541-545.
9. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375(9725):1545-1555.
10. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., Anderson L.J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999, 282(15):1440-1446.
11. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2095-2128.
12. Walsh E.E., Falsey A.R. Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets 2012, 12(2):98-102.
13. Campbell A.P., Chien J.W., Kuypers J., Englund J.A., Wald A., Guthrie K.A., et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis 2010, 201(9):1404-1413.
14. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140(6):543-546.
15. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163(4):693-698.
16. Kristensen K., Hjuler T., Ravn H., Simoes E.A., Stensballe L.G. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis 2012, 54(6):810-817.
17. DeVincenzo J.P., El Saleeby C.M., Bush A.J. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005, 191(11):1861-1868.
18. Houben M.L., Coenjaerts F.E., Rossen J.W., Belderbos M.E., Hofland R.W., Kimpen J.L., et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol 2010, 82(7):1266-1271.
19. Larranaga C.L., Ampuero S.L., Luchsinger V.F., Carrion F.A., Aguilar N.V., Morales P.R., et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr Infect Dis J 2009, 28(10):867-873.
20. Sheeran P., Jafri H., Carubelli C., Saavedra J., Johnson C., Krisher K., et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J 1999, 18(2):115-122.
21. Bennett B.L., Garofalo R.P., Cron S.G., Hosakote Y.M., Atmar R.L., Macias C.G., et al. Immunopathogenesis of respiratory syncytial virus bronchiolitis. J Infect Dis 2007, 195(10):1532-1540.
22. El Saleeby C.M., Bush A.J., Harrison L.M., Aitken J.A., Devincenzo J.P. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 2011, 204(7):996-1002.
23. Martin E.T., Kuypers J., Heugel J., Englund J.A. Clinical disease and viral load in children infected with respiratory syncytial virus or human metapneumovirus. Diagn Microbiol Infect Dis 2008, 62(4):382-388.
24. Wright P.F., Gruber W.C., Peters M., Reed G., Zhu Y., Robinson F., et al. Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis 2002, 185(8):1011-1018.
25. Hasegawa K., Jartti T., Mansbach J.M., Laham F.R., Jewell A.M., Espinola J.A., et al. Respiratory syncytial virus genomic load and disease severity among children hospitalized with bronchiolitis: multicenter cohort studies in the United States and Finland. J Infect Dis 2015 May 15, 211(10):1550-1559.
26. Mejias C., Yang C.-F., Garcia C., Khokhar S., Chavez-Bueno S., Somers C., et al. Respiratory syncytial virus (RSV) genetic variability and viral loads do not correlate with disease severity in children hospitalized with bronchiolitis. Infectious Diseases Society of America 48th Annual Meeting 2010, Vancouver, CA(October).
27. Jafri H.S., Wu X., Makari D., Henrickson K.J. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr Infect Dis J 2013 Apr, 32(4):335-340.
28. Garcia C., Soriano-Fallas A., Lozano J., Leos N., Gomez A.M., Ramilo O., et al. Decreased innate immune cytokine responses correlate with disease severity in children with respiratory syncytial virus and human rhinovirus bronchiolitis. Pediatr Infect Dis J 2012, 31(1):86-89.
29. Mehta R., Scheffler M., Tapia L., Aideyan L., Patel K.D., Jewell A.M., et al. Lactate dehydrogenase and caspase activity in nasopharyngeal secretions are predictors of bronchiolitis severity. Influenza Other Respir Viruses 2014, 8(6):617-625.
30. Mella C., Suarez-Arrabal M.C., Lopez S., Stephens J., Fernandez S., Hall M., et al. Innate immune dysfunction is associated with enhanced disease severity in infants with respiratory syncytial virus bronchiolitis. J Infect Dis 2013 Feb 15, 207(4):564-573.
31. Mella C., Hall M.W., Ramilo O., Mejias A. Reply to Plotz etal. J Infect Dis 2013, 208(11):1924-1925.
32. Bucasas K.L., Mian A.I., Demmler-Harrison G.J., Caviness A.C., Piedra P.A., Franco L.M., et al. Global gene expression profiling in infants with acute respiratory syncytial virus broncholitis demonstrates systemic activation of interferon signaling networks. Pediatr Infect Dis J 2013, 32(2):e68-76.
33. Ioannidis I., McNally B., Willette M., Peeples M.E., Chaussabel D., Durbin J.E., et al. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J Virol 2012, 86(10):5422-5436.
34. Mejias A., Ardura M.I., Garcia C., Torres E., Banchereau J., Chaussabel D., et al. Can disease activity be measured at the molecular level? Molecular distance to health assesses respiratory syncytial virus (RSV) disease severity. Children with bronchiolitis. Pediatric Academic Societies Annual Meeting; Vancouver, BC, Canada Abstract No 707 2010.
35. Ralston S.L., Lieberthal A.S., Meissner H.C., Alverson B.K., Baley J.E., Gadomski A.M., et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014, 134(5):e1474-e1502.
36. Emmett G.A. Bronchodilators for bronchiolitis-should they be used routinely?:...reducing waste in child health one intervention at a time. Evid Based Child Health: a Cochrane review journal 2014, 9(2):301-302.
37. Chowdhury M.M., McKenzie S.A., Pearson C.C., Carr S., Pao C., Shah A.R., et al. Heliox therapy in bronchiolitis: phase III multicenter double-blind randomized controlled trial. Pediatrics 2013, 131(4):661-669.
38. Zhang L., Mendoza-Sassi R.A., Wainwright C., Klassen T.P. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev 2008, (4):CD006458.
39. Buckingham S.C., Jafri H.S., Bush A.J., Carubelli C.M., Sheeran P., Hardy R.D., et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis 2002, 185(9):1222-1228.
40. van Woensel J.B., Vyas H., Group S.T. Dexamethasone in children mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus: a randomized controlled trial. Crit Care Med 2011, 39(7):1779-1783.
41. Plint A.C., Johnson D.W., Patel H., Wiebe N., Correll R., Brant R., et al. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med 2009, 360(20):2079-2089.
42. Corneli H.M., Zorc J.J., Majahan P., Shaw K.N., Holubkov R., Reeves S.D., et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007, 357(4):331-339.
43. Somers C.C., Ahmad N., Mejias A., Buckingham S.C., Carubelli C., Katz K., et al. Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial. Pediatr Allergy Immunol: official publication of the European Society of Pediatric Allergy and Immunology 2009, 20(5):477-485.
44. Bisgaard H., Flores-Nunez A., Goh A., Azimi P., Halkas A., Malice M.P., et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008, 178(8):854-860.
45. Ribavirin for respiratory syncytial virus infection in the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2004, (4): CD000181.pub2 [Internet].
46. American Academy of Pediatrics Respiratory syncytial virus. Red Book: 2012 report of the committee on infectious diseases 2012, 609-618. American Academy of Pediatrics, Elk Grove Village, IL. 29th ed. L.K.B. Pickering, C.J., D.W. Kimberlin, S.S. Long (Eds.).
47. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997, 99(1):93-99.
48. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102(3):531-537.
49. Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top F.H., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143(4):532-540.
50. Carbonell-Estrany X., Simoes E.A., Dagan R., Hall C.B., Harris B., Hultquist M., et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010, 125(1):e35-51.
51. American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014, 134(2):415-420.
52. Anderson L.J., Dormitzer P.R., Nokes D.J., Rappuoli R., Roca A., Graham B.S. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013, 31(Suppl. 2):B209-B215.
53. Empey K.M., Peebles R.S., Kolls J.K. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010, 50(9):1258-1267.
54. Shah J.N., Chemaly R.F. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011, 117(10):2755-2763.
55. Ramilo O., Lagos R., Saez-Llorens X., Suzich J., Wang C.K., Jensen K.M., et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J 2014 Jul, 33(7):703-709.
56. Robbie G.J., Criste R., Dall'acqua W.F., Jensen K., Patel N.K., Losonsky G.A., et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013, 57(12):6147-6153.
57. Ulbrandt N., Kallewaard N., Palaszynski S., Zhang J., Svabek C., McAuliffe J., et al. A next generation anti-RSV F monoclonal antibody as passive immunization for prevention of RSV disease in all infants. 9th International Respiratory Syncytial Virus Symposium; Cape Town, South Africa Abstract OP 27 2014.
58. Haynes L.M., Caidi H., Radu G.U., Miao C., Harcourt J.L., Tripp R.A., et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 2009, 200(3):439-447.
59. Detalle L., Larios A., Gallup L., Van Geelen A., Duprez L., Stohr T., et al. Delivery of ALX-0171 by inhalation greatly reduces disease burden in a neonatal lamb RSV infection model. 9th International Respiratory Syncytial Virus Symposium; Cape Town, South Africa Abstract OP 72 2014.
60. DeVincenzo J.P., Whitley R.J., Mackman R.L., Scaglioni-Weinlich C., Harrison L., Farrell E., et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014, 371(8):711-722.
61. Bonfanti J.F., Roymans D. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Dev 2009, 12(4):479-487.
62. Bonfanti J.F., Meyer C., Doublet F., Fortin J., Muller P., Queguiner L., et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem 2008, 51(4):875-896.
63. Chu H.Y., Englund J.A. Respiratory syncytial virus disease: prevention and treatment. Curr Top Microbiol Immunol 2013, 372:235-258.
64. DeVincenzo J., Lambkin-Williams R., Wilkinson T., Cehelsky J., Nochur S., Walsh E., et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010, 107(19):8800-8805.
65. Zamora M.R., Budev M., Rolfe M., Gottlieb J., Humar A., Devincenzo J., et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011, 183(4):531-538.
66. Devincenzo J., Fathi H., Mcclure M., Westland C., Chanda S., Lambkin-Williams R., et al. Treatment with oral ALS-008176, a nucleoside analog, rapidly reduces RSV viral load and clinical disease severity in a healthy volunteer challenge study 2014, IDWeek, Philadelphia, PA, Abstract #186, LB-1.
67. Chapman J., Abbott E., Alber D.G., Baxter R.C., Bithell S.K., Henderson E.A., et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 2007, 51(9):3346-3353.
68. Challa S., Scott A.D., Yuzhakov O., Zhou Y., Tiong-Yip C.L., Gao N., et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother 2014.
69. DeVincenzo J.P., Wilkinson T., Vaishnaw A., Cehelsky J., Meyers R., Nochur S., et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010, 182(10):1305-1314.
70. Jafri H.S., Chavez-Bueno S., Mejias A., Gomez A.M., Rios A.M., Nassi S.S., et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis 2004, 189(10):1856-1865.
71. Mejias A., Chavez-Bueno S., Rios A.M., Saavedra-Lozano J., Fonseca Aten M., Hatfield J., et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 2004, 48(5):1811-1822.
72. Mejias A., Chavez-Bueno S., Rios A.M., Aten M.F., Raynor B., Peromingo E., et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005, 49(11):4700-4707.
73. Simoes E.A., Groothuis J.R., Carbonell-Estrany X., Rieger C.H., Mitchell I., Fredrick L.M., et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007, 151(1):34-42. e1.
74. Simoes E.A., Carbonell-Estrany X., Rieger C.H., Mitchell I., Fredrick L., Groothuis J.R., et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 2010, 126(2):256-262.
75. Blanken M.O., Rovers M.M., Molenaar J.M., Winkler-Seinstra P.L., Meijer A., Kimpen J.L., et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013, 368(19):1791-1799.